Peritoneal Metastases From Colorectal Cancer
Conditions
Brief summary
The objective of this clinical trial is to demonstrate that cytoreductive surgery and patient-tailored hyperthermic intra-peritoneal chemotherapy (HIPEC) will increase efficacy in controlling peritoneal disease. Tridimensional cell cultures (organoids) derived from colorectal cancer peritoneal metastases are used to select the most active drugs in an in vitro HIPEC model on individual-patient level, based on the hypothesis that resistance to drug(s) routinely used for intraperitoneal delivery can explain peritoneal relapse after combined treatment, depending on the individual tumor biology;
Detailed description
This single-arm, single-center, open-label trial enrolls patients with limited and surgically resectable peritoneal metastases from colorectal cancer, no distant metastases, and no contraindication to major surgery. After signature of informed consent, patients undergo a preliminary laparoscopy to confirm diagnosis of peritoneal metastases, stage the disease, and obtain representative samples of peritoneal metastases. The investigators will use patient-derived organoids to select tailored hyperthermic intra-peritoneal chemotherapy (HIPEC) regimens in an in vitro model HIPEC. A set of candidate drugs suitable for intraperitoneal administration are tested on tumor-derived organoids under the same conditions as in the clinical practice (same drug combinations, concentration, exposure time, temperature). Different concentrations are tested to generate reproducible dose-response curves. Patients receive 3-6 month preoperative systemic chemotherapy with targeted agents, according to current guidelines. Those not experiencing disease progression during preoperative systemic chemotherapy will have cytoreductive surgery and HIPEC with drugs selected on the organoid-based preclinical model. Patients will undergo postoperative follow-up.
Interventions
PROCEDUREPatient-tailored hyperthermic intraperitoneal chemotherapy (HIPEC)
Patient-tailored HIPEC is performed by the closed-abdomen technique with the following drugs selected according to the results of the sensitivity tests on the organoid-based preclinical model: * Oxaliplatin 360 mg/mq for 30 min. * Oxaliplatin 200 mg/mq for 120 min. * Mitomycin-C 35mg/mq for 60 min. * Mitomycin-C 3.3 mg/mq/l of perfusate + cisplatin 25 mg/mq/l of perfusate for 60 min. (perfusate volume l. 4-6)
Sponsors
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. diagnosis of peritoneal metastases from intestinal-type or mucinous colo-rectal adenocarcinoma, by histological/cytological confirmation. 2. limited to moderate peritoneal involvement: peritoneal cancer index (PCI) ≤ 20; 3. peritoneal disease potentially amenable to complete surgical cytoreduction; 4. no evidence of hepatic, extra-regional nodal, or extra abdominal metastases 5. World Health Organization (WHO) performance status ≤2; 6. willingness to undergo preliminary laparoscopy, perioperative s-CT, and post-operative follow-up; 7. signature of informed consent.
Exclusion criteria
1. active sepsis; 2. impaired cardiac function (history of previous heart failure or 40% ejection fraction); 3. impaired renal function (serum creatinine \>1.5 normal value or creatinine clearance \< 60 ml/min); 4. impaired liver function (aspartate aminotransferase, alanine aminotransferase, bilirubin \> 1.5 normal value); 5. impaired bone marrow function (leukocytes \<4000/mm3, neutrophils \<1500/mm3, platelets \<80000/mm3); 6. impaired lung function (diagnosis of severe chronic obstructive pulmonary disease or 50% forced expiratory volume at one second or 40% diffusion capacity of lung for carbon monoxide adjusted for age); 7. dehydropyrimidine dehydrogenase deficiency; 8. pregnancy or lactation in progress; 9. haemorrhagic diathesis or coagulopathy; 10. any other condition or comorbidity that prevents safe administration of systemic chemotherapy (e.g. severe diarrhea, stomatitis or ulceration in the mouth or gastrointestinal tract); 11. psychiatric or neurological conditions that preclude the procedures of the protocol; 12. any contraindication to laparoscopy; 13. known hypersensitivity to any of the chemotherapy agents used for HIPEC in the present study and/or to any of their excipients; 14. history of previous malignancies treated in the last three years, excluding cutaneous spinocellular carcinoma and/or basocellular carcinoma; 15. previous cytoreductive surgery and HIPEC
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| One-year peritoneal metastasis-free survival | 12 months | Proportion of patients who remain free of peritoneal metastasis at a time interval of one year from the date of the combined procedure of cytoreductive surgery and patient-tailored hyperthermic intraperitoneal chemotherapy (HIPEC) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility of patient-tailored hyperthermic intraperitoneal chemotherapy (HIPEC) | 48 months | Feasibility will be determined as the number of patients who have cytoreductive surgery and patient-tailored hyperthermic intraperitoneal chemotherapy (HIPEC) among the total number of patients selected to be included in the study who sign the informed consent form |
| Overall survival | 60 months | Overall survival will be measured from the date of cytoreductive surgery and patient-tailored hyperthermic intraperitoneal chemotherapy (HIPEC) to the date of death for any cause or, for patients still alive at the date of the last available follow-up |
| Disease-free survival | 60 months | Disease-free survival will be measured from the date of cytoreductive surgery and patient-tailored hyperthermic intraperitoneal chemotherapy (HIPEC) to the date of peritoneal metastasis diagnosis, systemic metastases or death. |
| Safety of cytoreductive surgery and patient-tailored hyperthermic intraperitoneal chemotherapy (HIPEC) | 48 months | Proportion of patients who will suffer from postoperative complications after cytoreductive surgery and patient-tailored hyperthermic intraperitoneal chemotherapy (HIPEC) |
Countries
Italy
Contacts
Primary ContactDario Baratti, MD
Outcome results
None listed